Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?

被引：0
|
作者：
Khaki, Ali Raza [1 ,4 ]
Lythgoe, Mark P. [2 ]
Prasad, Vinay [3 ]
机构：
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[2] Imperial Coll London, London, England
[3] Univ Calif San Francisco, San Francisco, CA USA
[4] Stanford Univ, Sch Med, Clin E, 875 Blake Wilbur Dr, Stanford, CA 94305 USA
来源：
JOURNAL OF CANCER POLICY | 2023年 / 35卷
关键词：
ONCOLOGY;
D O I：
10.1016/j.jcpo.2023.100402
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] HOW VALID IS DISEASE-FREE SURVIVAL AS AN ENDPOINT IN ADJUVANT TRIALS
    CARTER, SK
    CONTROLLED CLINICAL TRIALS, 1980, 1 (02): : 177 - 178
  • [2] Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials
    Petrelli, Fausto
    Tomasello, Gianluca
    Ghidini, Michele
    Lonati, Veronica
    Passalacqua, Rodolfo
    Barni, Sandro
    HPB, 2017, 19 (11) : 944 - 950
  • [3] Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials
    Marconi, Lorenzo
    Sun, Maxine
    Beisland, Christian
    Klatte, Tobias
    Ljungberg, Boerje
    Stewart, Grant D.
    Dabestani, Saeed
    Choueiri, Toni K.
    Bex, Axel
    CLINICAL GENITOURINARY CANCER, 2021, 19 (02) : E92 - +
  • [4] Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials
    Yin, Jun
    Salem, Mohamed E.
    Dixon, Jesse G.
    Jin, Zhaohui
    Cohen, Romain
    DeGramont, Aimery
    Van Cutsem, Eric
    Taieb, Julien
    Alberts, Steven R.
    Wolmark, Norman
    Schmoll, Hans-Joachim
    Saltz, Leonard B.
    George, Thomas J.
    Goldberg, Richard R. M.
    Kerr, Rachel
    Lonardi, Sara
    Yoshino, Takayuki
    Yothers, Greg
    Grothey, Axel
    Andre, Thierry
    Shi, Qian
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2022, 114 (01): : 60 - 67
  • [5] Investigation of disease-free survival as a surrogate endpoint for survival in cancer clinical trials
    Chen, TT
    Simon, RM
    Korn, EL
    Anderson, SJ
    Lindblad, AS
    Wieand, HS
    Douglass, HO
    Fisher, B
    Hamilton, JM
    Friedman, MA
    COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 1998, 27 (06) : 1363 - 1378
  • [6] Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
    Run-Cong Nie
    Xue-Bin Zou
    Shu-Qiang Yuan
    Ying-Bo Chen
    Shi Chen
    Yong-Ming Chen
    Guo-Ming Chen
    Xiao-Jiang Chen
    Tian-Qi Luo
    Shu-Man Li
    Jin-Ling Duan
    Yun Wang
    Yuan-Fang Li
    BMC Cancer, 20
  • [7] Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a meta-analysis of 20 randomized controlled trials
    Nie, Run-Cong
    Zou, Xue-Bin
    Yuan, Shu-Qiang
    Chen, Ying-Bo
    Chen, Shi
    Chen, Yong-Ming
    Chen, Guo-Ming
    Chen, Xiao-Jiang
    Luo, Tian-Qi
    Li, Shu-Man
    Duan, Jin-Ling
    Wang, Yun
    Li, Yuan-Fang
    BMC CANCER, 2020, 20 (01)
  • [8] Appropriate Endpoint for Stage I NSCLC: Correlations of Long-Term Survival with Disease-Free and Recurrence-Free Survival
    Tan, Kay See
    Eguchi, Takashi
    Adusumilli, Prasad
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1463 - S1463
  • [9] Disease-free survival as the endpoint in multimodal rectal cancer trials: have we got this right?
    Fokas, Emmanouil
    Roedel, Claus
    Smith, J. Joshua
    Garcia-Aguilar, Julio
    Buyse, Marc
    Glynne-Jones, Robert
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 962 - 964
  • [10] Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis
    Oba, Koji
    Paoletti, Xavier
    Alberts, Steven
    Bang, Yung-Jue
    Benedetti, Jacqueline
    Bleiberg, Harry
    Catalano, Paul
    Lordick, Florian
    Michiels, Stefan
    Morita, Satoshi
    Ohashi, Yasuo
    Pignon, Jean-pierre
    Rougier, Philippe
    Sasako, Mitsuru
    Sakamoto, Junichi
    Sargent, Daniel
    Shitara, Kohei
    Cutsem, Eric Van
    Buyse, Marc
    Burzykowski, Tomasz
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (21): : 1600 - 1607
12345